Prognostic Factors of Survival in a Randomized Phase III Trial (MPACT) of Weekly nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Pancreatic Cancer

BACKGROUND. nab-Paclitaxel in combination with gemcitabine has emerged as a new treatment option for patients with metastatic pancreatic cancer (MPC), based on superiority over gemcitabine demonstrated in the phase III MPACT trial. Previously, Karnofsky performance status (KPS) score and the presenc...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncologist
Glavni autori: Tabernero, Josep, Chiorean, E. Gabriela, Infante, Jeffrey R., Hingorani, Sunil R., Ganju, Vinod, Weekes, Colin, Scheithauer, Werner, Ramanathan, Ramesh K., Goldstein, David, Penenberg, Darryl N., Romano, Alfredo, Ferrara, Stefano, Von Hoff, Daniel D.
Format: Artigo
Jezik:Inglês
Izdano: AlphaMed Press 2015
Teme:
Gastrointestinal Cancer
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4319641/
https://ncbi.nlm.nih.gov/pubmed/25582141
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2014-0394
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items